Glized-M Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, resulting in reduced blood glucose levels. This combination therapy offers complementary mechanisms of action, making it effective in patients inadequately controlled on diet and exercise alone or on monotherapy. Glized-M Tablet PR is designed for prolonged release, ensuring sustained plasma concentrations and improved patient compliance through once-daily dosing. It is essential to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, which often subside with continued use. Hypoglycemia risk is primarily associated with Glimepiride, necessitating patient education on recognizing and managing low blood sugar episodes. Glized-M Tablet PR should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.